Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Lotus Pharmaceuticals reports $5.4 million net earnings for third-quarter 2009

Lotus Pharmaceuticals, Inc. a growing developer and producer of prescriptions drugs and licensed national seller of pharmaceutical products in the People's Republic of China, today reported third-quarter 2009 net earnings were $5.4 million, or $0.11 per diluted share, compared with $3.2 million, or $0.07 per diluted share, in 2008. Net revenues were $14.5 million during the third quarter of 2009, compared with $16.7 million in the third quarter of 2008.

16 Nov 2009

Transcendental Meditation lowers rates of heart attack, stroke, and death

Patients with coronary heart disease who practiced the stress-reducing Transcendental Meditation® technique had nearly 50 percent lower rates of heart attack, stroke, and death compared to nonmeditating controls, according to the results of a first-ever study presented during the annual meeting of the American Heart Association in Orlando, Fla., on Nov.16, 2009.

16 Nov 2009

Findings from post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse announced

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse-. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years.

16 Nov 2009

Effect of niacin or ezetimibe added to chronic statin therapy on carotid intima media thickness: Study

In combination with statins, adding a medication that raises high-density lipoprotein (HDL) cholesterol was more effective in reversing artery wall plaque buildup and in reducing heart disease risk than adding a drug that lowers low-density lipoprotein (LDL) cholesterol, researchers reported today at the American Heart Association Scientific Sessions 2009.

16 Nov 2009

Effects of vitamin D deficiency amplified by lower levels of sex hormone estrogen

Researchers at Johns Hopkins are reporting what is believed to be the first conclusive evidence in men that the long-term ill effects of vitamin D deficiency are amplified by lower levels of the key sex hormone estrogen, but not testosterone.

16 Nov 2009

Merck to market and develop cardiovascular medicines for a range of cardiovascular disorders

Following the completion of its merger with Schering-Plough, Merck today confirms and underscores its commitment to marketing and developing cardiovascular medicines for a range of cardiovascular disorders.

16 Nov 2009

Study confirms that people with severe mental disorders more at risk of dying from heart disease

A large new study confirms that people with severe mental disorders — such as schizophrenia or other psychotic disorders — are 25 percent to 40 percent more prone to die from heart disease than people without mental illness are.

13 Nov 2009

Decreased heart functions associated with fat collection in different body locations: Study

Researchers from Boston University School of Medicine (BUSM) have shown that fat collection in different body locations, such as around the heart and the aorta and within the liver, are associated with certain decreased heart functions. The study, which appears on-line in Obesity, also found that measuring a person's body mass index (BMI) does not reliably predict the amount of undesired fat in and around these vital organs.

13 Nov 2009

Easy and affordable genetic test from Pathway Genomics

Pathway Genomics™ (www.PATHWAY.com), a privately held, venture-backed company, today announced an exclusive agreement to partner with OptumHealthSM Allies and offer the organization’s 15 million members a 20% discount on Pathway’s Health and Ancestry genetic test.

13 Nov 2009

Peer-reviewed article to evaluate the financial benefit of wellness programs

URAC, the nation's leading health care accreditation and education organization, today announced that the value of its Comprehensive Wellness Accreditation standards is referenced in "Framework for Assessing the Financial Benefit of Wellness Program", an article by Thomas Wilson, PhD, DrPH, a wellness expert and an epidemiologist for Trajectory Healthcare, LLC.

13 Nov 2009

Shire announces findings from Phase 3 study data with Vyvanse

Shire plc, the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse®. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years.

13 Nov 2009

Health Canada approves ONGLYZA for type 2 diabetes treatment

Bristol-Myers Squibb Canada and AstraZeneca Canada today announced that Health Canada has approved ONGLYZA(TM) (saxagliptin) which improves all three key measures of glycemic control - hemoglobin A1c (A1c), fasting plasma glucose (FPG) and post-prandial glucose (PPG) - when taken in combination with other commonly used oral anti-diabetic agents (metformin or a sulfonylurea).

13 Nov 2009

Nonprofit organizations receive a total of $4.6 million in grants from Edwards Lifesciences Fund

Edwards Lifesciences Corporation, the global leader in the science of heart valves and hemodynamic monitoring, today announced that The Edwards Lifesciences Fund is granting $1.8 million to 107 nonprofit organizations as part of its fifth annual grant cycle. This fund is a donor-advised fund of the Vanguard Charitable Endowment Program.

13 Nov 2009

LA BioMed to participate in a national study of the effectiveness of testosterone

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) announced today that it will participate in a large national study of the effectiveness of testosterone as a treatment for anemia, cardiovascular disease, decreased vitality, impaired memory and sexual function, loss of muscle mass and other health conditions that affect older men.

13 Nov 2009

UT Southwestern Medical Center awarded $42M for basic and patient-oriented research

UT Southwestern Medical Center has been awarded more than $42 million to date for basic and patient-oriented research from the American Recovery and Reinvestment Act of 2009, the $787 billion stimulus package President Barack Obama signed into law in February.

13 Nov 2009

New Cat B 750 FAST imaging agent launched by VisEn Medical

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new Cat B 750 FAST(TM) imaging agent for measuring and monitoring cathepsin B activity associated with disease progression and therapeutic response in vivo. Cathepsin B expression is well known as a key biomarker and therapeutic target in a range of diseases, including atherosclerosis, oncology, and arthritis.

12 Nov 2009

Scientists find way to disarm "undruggable" protein; discovery lays foundation for new kind of cancer therapy

Scientists have devised an innovative way to disarm a key protein considered to be "undruggable," meaning that all previous efforts to develop a drug against it have failed. Their discovery, published in the November 12 issue of Nature, lays the foundation for a new kind of therapy aimed directly at a critical human protein — one of a few thousand so-called transcription factors — that could someday be used to treat a variety of diseases, especially multiple types of cancer.

12 Nov 2009

Data from Phase IIa clinical trial evaluating VT-111 to be presented by Viron Therapeutics at AHA conference

Viron Therapeutics Inc., a biopharmaceutical company pioneering the development of viral protein therapeutics, announced today that the Company's research collaborator, Dr. Jean-Claude Tardif, Director of the Research Center at the Montreal Heart Institute, will present data from a Phase IIa clinical trial evaluating VT-111 at the American Heart Association (AHA) Scientific Sessions 2009 conference. The conference will take place in Orlando, Florida from November 14 to 18, 2009.

12 Nov 2009

Hualapai Mountain Medical Center receives licensure by the Arizona Department of Health Services

MedCath Corporation, a healthcare provider focused on high acuity healthcare services, today announced it has received licensure by the Arizona Department of Health Services and accreditation by The Joint Commission for its new 70-bed Hualapai Mountain Medical Center in Kingman, Ariz, which opened October 15th.

12 Nov 2009

Researchers find link between telomeres and longevity

A team led by researchers at Albert Einstein College of Medicine of Yeshiva University has found a clear link between living to 100 and inheriting a hyperactive version of an enzyme that rebuilds telomeres - the tip ends of chromosomes. The findings appear in the latest issue of the Proceedings of the National Academy of Sciences.

12 Nov 2009

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Lotus Pharmaceuticals reports $5.4 million net earnings for third-quarter 2009

Transcendental Meditation lowers rates of heart attack, stroke, and death

Findings from post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse announced

Effect of niacin or ezetimibe added to chronic statin therapy on carotid intima media thickness: Study

Effects of vitamin D deficiency amplified by lower levels of sex hormone estrogen

Merck to market and develop cardiovascular medicines for a range of cardiovascular disorders

Study confirms that people with severe mental disorders more at risk of dying from heart disease

Decreased heart functions associated with fat collection in different body locations: Study

Easy and affordable genetic test from Pathway Genomics

Peer-reviewed article to evaluate the financial benefit of wellness programs

Shire announces findings from Phase 3 study data with Vyvanse

Health Canada approves ONGLYZA for type 2 diabetes treatment

Nonprofit organizations receive a total of $4.6 million in grants from Edwards Lifesciences Fund

LA BioMed to participate in a national study of the effectiveness of testosterone

UT Southwestern Medical Center awarded $42M for basic and patient-oriented research

New Cat B 750 FAST imaging agent launched by VisEn Medical

Scientists find way to disarm "undruggable" protein; discovery lays foundation for new kind of cancer therapy

Data from Phase IIa clinical trial evaluating VT-111 to be presented by Viron Therapeutics at AHA conference

Hualapai Mountain Medical Center receives licensure by the Arizona Department of Health Services

Researchers find link between telomeres and longevity

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in